Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA)
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus
Sponsor: Gilead Sciences
Listed as NCT01425359, this PHASE4 trial focuses on Angina Pectoris and Coronary Artery Disease and remains completed. Sponsored by Gilead Sciences, it has been updated 8 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alexandria, United States , Alpena, United States , Ashkelon, Israel , Augusta, United States , Bardejov, Slovakia , Barnaul, Russia , Belgrade, Serbia , Berlin, Germany , Be’er Ya‘aqov, Israel , Bielefeld, Germany and 78 more locations